wanglexin wang

Mr. wanglexin wang


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Cell Proliferation
Verified
Journal Article
Open access
FMFeng Ma
Feng Ma
WWwanglexin wang
wanglexin wang
HCHao Chi
Hao Chi
XLXinyi Li
Xinyi Li
YXYaoqin Xu
Yaoqin Xu
XYXiaoling Yang
Xiaoling Yang
Osteoarthritis (OA) is a prevalent and debilitating joint disorder that affects millions of individuals worldwide, severely impairing mobility, independence, and quality of life. Emerging evidence suggests that ferroptosis is a critical factor in OA pathogenesis. However, its precise involvement and underlying mechanisms remain poorly understood. In this study, we first identified that cartilage intermediate layer protein (CILP) mediates the regulation of ferroptosis‐related genes in OA through hdWGCNA analysis combined with single‐cell RNA sequencing. Further investigation revealed a significant upregulation of CILP protein expression in C28/I2 cells under LPS induction. Mechanistically, bioinformatics analysis identified differentially expressed miRNAs; qRT‐PCR combined with a dual‐luciferase experiment revealed that miR‐140‐3p was downregulated and directly targets CILP. Experimental data further demonstrated that miR‐140‐3p regulates ferroptosis, inflammation, and oxidative stress by targeting CILP. These findings offer valuable insights into the molecular mechanisms of the miR‐140‐3p/CILP axis in regulating ferroptosis, inflammation, and oxidative stress, thus providing a foundation for developing therapeutic strategies for OA.

21 October 2024 in BioFactors
Verified
Journal Article
Closed access
JTJing Tang
Jing Tang
WWWei Wei
Wei Wei
YXYaoqing Xu
Yaoqing Xu
KCKexin Chen
Kexin Chen
YMYaping Miao
Yaping Miao
WWwanglexin wang
wanglexin wang

11 September 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
QXQianping Xu
Qianping Xu
CLChao Liu
Chao Liu
HWHailin Wang
Hailin Wang
SLShujuan Li
Shujuan Li
HYHanshen Yan
Hanshen Yan
WWwanglexin wang
wanglexin wang
Background Colorectal cancer (CRC) is the third most prevalent cancer worldwide, with the tumor microenvironment (TME) playing a crucial role in its progression. Aggregated autophagy (AA) has been recognized as a factor that exacerbates CRC progression. This study aims to study the relationship between aggregated autophagy and CRC using single-cell sequencing techniques. Our goal is to explain the heterogeneity of the TME and to explore the potential for targeted personalized therapies. Objective To study the role of AA in CRC, we employed single-cell sequencing to discern distinct subpopulations within the TME. These subpopulations were characterized by their autophagy levels and further analyzed to identify specific biological processes and marker genes. Results Our study revealed significant correlations between immune factors and both clinical and biological characteristics of the tumor microenvironment (TME), particularly in cells expressing TUBA1B and HSP90AA1. These immune factors were associated with T cell depletion, a reduction in protective factors, diminished efficacy of immune checkpoint blockade (ICB), and enhanced migration of cancer-associated fibroblasts (CAFs), resulting in pronounced inflammation. In vitro experiments showd that silencing TUBA1B and HSP90AA1 using siRNA (Si-TUBA1B and Si-HSP90AA1) significantly reduced the expression of IL-6, IL-7, CXCL1, and CXCL2 and inhibition of tumor cell growth in Caco-2 and Colo-205 cell lines. This reduction led to a substantial alleviation of chronic inflammation and highlighted the heterogeneous nature of the TME. Conclusion This study marks an initial foray into understanding how AA-associated processes may potentiate the TME and weaken immune function. Our findings provide insights into the complex dynamics of the TME and highlight potential targets for therapeutic intervention, suggesting a key role for AA in the advancement of colorectal cancer.

6 January 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YCYuxuan Chen
Yuxuan Chen
HYHaisheng Yan
Haisheng Yan
YXYaoqin Xu
Yaoqin Xu
KCKexin Chen
Kexin Chen
RYRunqin Yang
Runqin Yang
WWwanglexin wang
wanglexin wang
Background Currently, serum PSA is the most commonly used screening tool in clinical practice. However, PSA levels in the range of 4–10 ng/ml are considered the ‘grey zone’ of prostate cancer screening. Patients within this range need to be further evaluated using additional parameters such as PSA ratio, PSA density, and other indices to determine the necessity of prostate biopsy (PBx). Despite this, patients in the ‘grey zone’ still have a low rate of positive biopsy results. Neutrophils have been found to be associated with tumor development and inflammation. Based on this, we combined PSA and absolute neutrophil counts to calculate the total PSA to absolute neutrophil ratio (PNR), which is higher in patients with prostate cancer and lower in those with benign conditions. PNR is elevated in prostate cancer patients compared to those with prostate enlargement. Therefore, the aim of this study is to explore the diagnostic efficacy of PNR for prostate cancer across different PSA intervals and to provide new insights into the diagnosis, treatment, and screening strategies for prostate cancer. Objective In this study, we explored the predictive value of prostate-specific antigen-to-neutrophil ratio (PNR) for the diagnosis of prostate cancer, with a view to further improving the diagnostic accuracy of prostate cancer. Methods Patients were grouped in three different divisions of PSA 4–10 ng/ml, 10–20 ng/ml, > 20 ng/ml, We grouped the patients and compared the test data such as age, PSA, PSA-density (PSAD), and prostate-specific antigen-to-neutrophil ratio (PNR) between the two groups of patients who had puncture results of prostate cancer and non-prostate cancer at the same time using Log regression test to verify the diagnostic value of PNR. Results When PSA levels are in the range of 4–10 ng/ml, an elevated PNR is an independent risk factor for prostate cancer. In this range, the diagnostic value of f/t PSA and PSAD for prostate cancer is limited. However, the use of PNR can significantly enhance the diagnostic efficacy for prostate cancer and thereby effectively reduce the incidence of unnecessary prostate biopsies.

27 December 2011 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
MDMing-Feng Dong
Ming-Feng Dong
ZMZeng-Shan Ma
Zeng-Shan Ma
SMSheng-Jun Ma
Sheng-Jun Ma
SCShou-Dong Chai
Shou-Dong Chai
PTPei-Zhe Tang
Pei-Zhe Tang
WWwanglexin wang
wanglexin wang
Objective: To evaluate the therapeutic effects of prostaglandin E1 (PGE1) on residual pulmonary arterial hypertension (PAH) after corrective surgery for congenital heart disease. Methods: Thirty-one patients with postoperational PAH were randomly divided into control group (n = 15) and PGE1 group (n = 16, 6 courses of intravenous PGE1 plus conventional therapy). Mean pulmonary arterial pressure (MPAP), right ventricular ejection fraction (RVEF), and left ventricular ejection fraction (LVEF) were measured by echocardiography before and 3, 6, and 12 months after the treatment. Arterial oxygen pressure (Pao2) was monitored. Results: In both groups, MPAP decreased and RVEF, LVEF, and Pao2 increased at 6 and 12 months following surgery. In the PGE1 group, the MPAP (32.2 ± 5.2 vs 40.2 ± 5.1 mm Hg; P = .008) was lower and RVEF (66.6% ± 6.5% vs 54.9% ± 2.1%; P = .019), LVEF (65.9% ± 3.9% vs 53.5% ± 5.1%; P = .031), and Pao2 (94.3% ± 11.2% vs 93.1% ± 11.3%; P = .009) was higher than in the control group 12 months after the surgery. Four patients (26.7%) in the control group died of pulmonary hypertension crisis, but there was no death in the PGE1 group ( P = .029). Cumulative survival rate in the control group were 86.7%, 80%, 73.3%, and 73.3% at 1, 2, 3, and 5 years, respectively. Conclusions: Intravenous PGE1 therapy after corrective surgery for congenital heart disease was associated with a reduction in mean pulmonary arterial pressure and a lower risk of death.

1 March 2000 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
WWwanglexin wang
wanglexin wang